Histologically confirmed PD-L1 status defined NSCLC. Biopsy must be within 70 days of first treatment with pembrolizumab. 
ECOG performance status 2. 
Life expectancy > 12 weeks. 
Uni-dimensionally measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 
Computerised Tomography (CT) scan of chest and abdomen within 28 days of starting pembrolizumab. 
Adequate haematological function: 
Platelet count ≥100 x 109 /L. 
Neutrophils ≥1.5 x 109/L. 
Haemoglobin ≥ 9g/dL. 
Adequate hepatic function: 
Serum bilirubin ≤1.5 x upper limit of normal (ULN). 
Serum transaminases ≤2.5 x ULN. 
Adequate renal function: Creatinine clearance <1.5 times ULN concurrent with creatinine clearance >50 ml/min. 
Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses. 
